Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Rip currents are powerful, narrow channels of fast-moving water flowing from the shore to deeper lake water. They can happen quickly and are responsible for dozens of rescues and fatalities on the ...